Reversible cardiomyopathy in paediatric Addison's disease--a cautionary tale.
A 13 year-old girl with clinical features of Addison's disease developed acute cardiac failure after initiation of treatment and after initial clinical improvement. Large doses of i.v. hydrocortisone and oral fludrocortisone, in addition to inotropic and ventilatory support, were required to achieve cardiovascular stability. The cardiomyopathy improved over one week and her condition then remained stable on oral glucocorticoid and mineralocorticoid replacement therapy. Reversible cardiomyopathy is a rare and potentially life-threatening complication of Addison's disease. The second reported paediatric patient is presented, the only one reported to require ventilatory support.
Conwell
L S
LS
Department of Endocrinology and Diabetes Royal Children's Hospital, Brisbane, Queensland, Australia. louise_conwell@health.qld.gov.au
Gray
L M
LM
Delbridge
R G
RG
Thomsett
M J
MJ
Batch
J A
JA
D000224:Addison Disease / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D000284:Administration, Oral; D000293:Adolescent; D001315:Australia; D002311:Cardiomyopathy, Dilated / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004280:Dobutamine / Q000494:pharmacology / Q000627:therapeutic use; D004298:Dopamine / Q000494:pharmacology / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004452:Echocardiography; D005260:Female; D005438:Fludrocortisone / Q000008:administration & dosage / Q000627:therapeutic use; D005440:Fluid Therapy; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000627:therapeutic use; D007275:Injections, Intravenous; D013997:Time Factors; D016896:Treatment Outcome
D002316:Cardiotonic Agents; D004280:Dobutamine; D005438:Fludrocortisone; D004298:Dopamine; D006854:Hydrocortisone